• Indications: Nerlynx® (neratinib) tablets, for oral use, is a kinase inhibitor indicated:

    • As a single agent, for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy.
    • In combination with capecitabine, for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.
  • Programs to help support your patients

    Use the following resources to get your eligible patients started on Nerlynx

    Enrollment Form

    English
    Español
    Sample letter of medical
    necessity
    Download

    The Nerlynx patient co-pay card is available

    Puma Biotechnology offers co-pay assistance to help qualified commercially insured patients with the cost of their Nerlynx prescription

    Nerlynx co-pay card
    • Eligible commercially insured patients treated with Nerlynx may pay as little as $10 per prescription.* Patients can be enrolled through their specialty pharmacy. To verify your patients’ eligibility or to enroll them in the co-pay card program, visit this website or call Puma Patient Lynx at 1-855-816-5421

    National Drug Code (NDC) for Nerlynx 40 mg film-coated tablets

    Package sizeNDC
    133 tabletsNDC 70437-240-33
    180 tabletsNDC 70437-240-18

    Use the 133-tablet NDC for the first month of treatment when initiating dose escalation for Nerlynx.

    Limitations apply. Patient must have commercial insurance. Offer is not valid under Medicare, Medicaid, or any other federal or state program. Puma Biotechnology reserves the right to rescind, revoke, or amend this program without notice. For full terms and conditions, call 1-855-816-5421.

    Support for patients prescribed Nerlynx

      Access & coverage

    • Benefits Verification & Prior Authorization Assistance

      This program provides comprehensive support, including benefits investigation to verify insurance coverage and assistance with prior authorization.

    • Nerlynx Quick Start

      Provides a free 3-week supply of NERLYNX to eligible patients experiencing delays in gaining access to therapy.

    • Co-Pay Assistance

      Eligible commercially insured patients treated with NERLYNX may pay as little as $10 per prescription. Patients can be enrolled through their specialty pharmacy or through the Access and Support page on nerlynx.com.

    • Financial Support Information

      For patients with financial needs, we will work to find appropriate sources for support.

    • Ongoing Treatment

    • Nerlynx Mentor Program

      Patient mentors provide confidential support for patients who are considering or currently taking NERLYNX.*

    • Product Support

      Our specialty pharmacy network will provide patients with product education and side-effect counseling to help them better understand and manage their NERLYNX therapy.

    • Nurse Call Center

      Our staff of registered nurses by training are available to speak with patients and healthcare providers to answer questions about NERLYNX. The call center is open Monday to Friday, 9 AM to 8 PM ET, for your convenience. Call 1-855-816-5421 (when prompted, press 2). Bilingual nurses are available.

    • Text Message Support

      Patients can sign up to receive medication reminders and motivational messages to support treatment adherence.

    • Mentors are compensated for their time.
    • This is an informational service. Call center nurses do not offer medical advice.

    Specialty distributors

    Current as of August 2022

    • Cardinal Health™ Specialty SolutionsT: (866) 677-4844www.cardinalhealth.com
    • McKesson Plasma and BiologicsT: (877) 625-2566www.mckesson.com/plasmabiologics
    • McKesson Specialty HealthT: (800) 482-6700www.mckessonspecialtyhealth.com
    • ASD HealthcareT: (800) 746-6273www.asdhealthcare.com

    Specialty pharmacy network

    Current as of August 2022

    • AcariaHealth™T: (800) 511-5144 F: (877) 541-1503www.acariahealth.comHours of operation: M-F, 8 am-10 pm (ET)
    • Biologics, Inc.T: (800) 850-4306 F: (800) 823-4506www.biologicsinc.comHours of operation: M-F, 8 am-8 pm (ET)
    • Optum® Specialty PharmacyT: (877) 445-6874 F: (877) 342-4596specialty.optumrx.comHours of operation: M-F, 8 am-10 pm (ET); Sat., 9 am-8 pm (ET)
    • Accredo® Health Group, Inc.T: (877) 732-3431 F: (866) 352-3973www.accredo.comHours of operation: M-F, 8 am-8 pm (ET)
    • CVS Specialty PharmacyT: (844) 239-4761 F: (855) 296-0210www.cvsspecialty.comHours of operation: M-F, 8:30 am-8:30 pm (ET)
    • Onco360 Oncology PharmacyT: (877) 662-6633 F: (877) 662-6355www.onco360.comHours of operation: M-F, 8 am-7 pm (ET); Sat., 9 am-2 pm (ET)

    Support for patients prescribed NERLYNX*

    • Access and coverage
    • Ongoing patient support

    Puma Patient Lynx programs are subject to change or to be discontinued without notice. Limitations apply and certain programs are subject to eligibility criteria. For full terms and conditions, call 1-855-816-5421.

    Download the Nerlynx Dosing and Administration Guide for additional information to help your patients get started with Nerlynx

    Download

    Important Safety Information and Indications

    Contraindications: None

    Warnings and Precautions:

    • Diarrhea: Manage diarrhea through either Nerlynx dose escalation or loperamide prophylaxis. If diarrhea occurs despite recommended prophylaxis, treat with additional antidiarrheals, fluids, and electrolytes as clinically indicated. Withhold Nerlynx in patients experiencing severe and/or persistent diarrhea. Permanently discontinue Nerlynx in patients experiencing Grade 4 diarrhea or Grade ≥2 diarrhea that occurs after maximal dose reduction.
    • Hepatotoxicity: Monitor liver function tests monthly for the first 3 months of treatment, then every 3 months while on treatment and as clinically indicated. Withhold Nerlynx in patients experiencing Grade 3 liver abnormalities and permanently discontinue Nerlynx in patients experiencing Grade 4 liver abnormalities.
    • Embryo-Fetal Toxicity: Nerlynx can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception.

    Adverse Reactions: The most common adverse reactions (reported in ≥5% of patients) were:

    • Nerlynx as a single agent: diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increased, nail disorder, dry skin, abdominal distention, epistaxis, weight decreased, and urinary tract infection.
    • Nerlynx in combination with capecitabine: diarrhea, nausea, vomiting, decreased appetite, constipation, fatigue/asthenia, weight decreased, dizziness, back pain, arthralgia, urinary tract infection, upper respiratory tract infection, abdominal distention, renal impairment, and muscle spasms.

    To report suspected adverse reactions, contact Puma Biotechnology, Inc. at 1-844-Nerlynx (1-844-637-5969) or FDA at 1-800-332-1088 or www.fda.gov/medwatch.

    Drug Interactions:

    • Gastric acid reducing agents: Avoid concomitant use with proton pump inhibitors. Separate Nerlynx by at least 2 hours before or 10 hours after H2-receptor antagonists. Or separate Nerlynx by at least 3 hours after antacids.
    • Strong CYP3A4 inhibitors: Avoid concomitant use.
    • P-gp and moderate CYP3A4 dual inhibitors: Avoid concomitant use.
    • Strong or moderate CYP3A4 inducers: Avoid concomitant use.
    • Certain P-gp substrates: Monitor for adverse reactions of P-gp substrates for which minimal concentration change may lead to serious adverse reactions when used concomitantly with Nerlynx.

    Use In Specific Populations:

    • Lactation: Advise women not to breastfeed.

    Please see Full Prescribing Information.

    Indications: Nerlynx® (neratinib) tablets, for oral use, is a kinase inhibitor indicated:

    • As a single agent, for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy.
    • In combination with capecitabine, for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.
    Terms of use  |  Privacy policy  |  Site map  |  Contact us
    Nerlynx is a registered trademark and Puma Patient Lynx is a trademark of Puma Biotechnology, Inc.
    © 2023 Puma Biotechnology, Inc. All rights reserved.
    PRC-US-NER-3115 10/23